Opus Genetics

IRD

Market cap $252M

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review Company expects to initiate Phase 3 dosing in 4Q 2026 RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) in a Type B Rare Disease Evidence Principles (RDEP) meeting on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated IRD, an early-onset severe inherited retinal dystrophy.

RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000®, the Russell 2000® and the Russell Microcap® Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution.

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics' Pipeline RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), hosted a Research and Development (R&D) Science Forum where management and leading IRD experts highlighted the Company's expanding gene therapy pipeline for severe retinal diseases.

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET.

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company.

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m.

Opus Genetics NASDAQ: IRD is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets' 2026 Global Healthcare Conference.